Abstract
In our previous phase I study of temozolomide in patients with acute leukemia, temozolomide was well tolerated and demonstrated significant anti-leukemic activity. The maximum tolerated dose was 200 mg/m2/d for 7 days, repeated approximately every 5-6 weeks. In the current study, we evaluated the same dose of temozolomide in patients with myelodysplastic syndrome. Fourteen patients received 19 courses of temozolomide. The median age was 71 years. In this study, treatment was poorly tolerated with patients requiring admission in 9 of 19 courses. Toxicity included worsening cytopenias, neutropenic fever, and exacerbation of cardiac disease, the latter due to worsening anemia. An unusual finding was the development of leukocytoclastic vasculitis in 4 patients. There were no formal responses to therapy. The current schedule of temozolomide is not efficacious in patients with myelodysplastic syndrome.
References
Aug 1, 1992·Anti-cancer Drugs·P TavernaM D'Incalci
Sep 5, 1995·Biochemical and Biophysical Research Communications·K InokuchiT Shimada
Jan 1, 1995·Leukemia & Lymphoma·C AulW Schneider
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S M O'ReillyP Lewis
Feb 3, 1997·Mutation Research·M J Armstrong, S M Galloway
Dec 24, 1997·British Journal of Haematology·J J MolldremA J Barrett
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K YungV A Levin
Apr 18, 2000·Mutation Research·A E Pegg
Jul 27, 2001·Carcinogenesis·R PepponiS D'Atri
Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·N L HarrisC D Bloomfield
Apr 26, 2002·British Journal of Haematology·Mohammad H SheikhhaJohn A Liu Yin
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karen SeiterTauseef Ahmed
Aug 30, 2002·Leukemia·M OosterveldUNKNOWN EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center
Dec 17, 2002·Leukemia & Lymphoma·Lenka Krsková-HonzátkováZuzana Sieglová
Jan 23, 2003·The Journal of Pharmacology and Experimental Therapeutics·Rita PepponiStefania D'Atri